Skip to content

US · ISRG · MEDICAL - INSTRUMENTS & SUPPLIES

Intuitive Surgical, Inc. (ISRG) intrinsic value and stock valuation

$399.05as of 2026-11-21 · Mkt cap 132.55B

Data updated · price as of 2026-11-21

OvervaluedIC value is 20–50% below the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Intuitive Surgical, Inc. DCF and intrinsic value

InvestorsCraft values ISRG with the Chepakovich two-stage DCF model — currently rated overvalued. How the model works · Run your own DCF prefilled from ISRG’s statements →

Intuitive Surgical, Inc. Graham Number

Graham Number: $95.14d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →

Healthcare · Medical - Instruments & Supplies Sunnyvale, CA 94086-5304 intuitive.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$10.1B+18.2% 5y CAGRd
20112025
Net income
$2.86B+21.9% 5y CAGRd
20112025
Free cash flow
$2.49B+16.9% 5y CAGRd
20112025
Total equity
$17.9B+12.9% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$10.1B$8.35B$7.12B$6.22B$5.71B
Operating income$2.95B$2.35B$1.77B$1.58B$1.82B
Net income$2.86B$2.32B$1.8B$1.32B$1.7B
EPSd$7.87M$6.42M$5.03M$3.65M$4.66M
Operating cash flow$3.03B$2.42B$1.81B$1.49B$2.09B
Capital expenditure-$-539.8M-$-1.11B-$-1.06B-$-532.4M-$-353.5M
Free cash flow$2.49B$1.3B$749.6M$958.4M$1.74B
Total assets$20.6B$18.8B$15.4B$13B$13.6B
Total debt$302.8M$146M$0.00$0.00$87M
Net debt-$-3.07B-$-1.88B-$-2.75B-$-1.58B-$-1.2B
Total equity$17.9B$16.5B$13.4B$11.1B$12B
Cash and short-term investments$5.93B$4.01B$5.22B$4.12B$4.23B
Income statement
20252024202320222021
Revenue$10.1B$8.35B$7.12B$6.22B$5.71B
Cost of revenue$3.42B$2.72B$2.39B$2.03B$1.75B
Gross profit$6.64B$5.63B$4.73B$4.2B$3.96B
Research and development expenses$1.31B$1.15B$998.8M$879M$671M
Selling, general and administrative expenses$2.39B$2.14B$1.96B$1.74B$1.47B
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$3.7B$3.29B$2.96B$2.62B$2.14B
Cost and expenses$7.12B$6B$5.36B$4.65B$3.89B
Interest income$365.9M$324.9M$192.1M$29.7M$69.3M
Interest expense$0.00$0.00$0.00$0.00$0.00
Depreciation and amortization$677.1M$462M$402.2M$365.8M$317M
Ebitda$3.99B$3.14B$2.36B$1.97B$2.21B
Operating income$2.95B$2.35B$1.77B$1.58B$1.82B
Total other income/expenses, net$365.9M$324.9M$192.1M$29.7M$69.3M
Income before tax$3.31B$2.67B$1.96B$1.61B$1.89B
Income tax expense$434.8M$336.3M$141.6M$262.4M$162.2M
Net income$2.86B$2.32B$1.8B$1.32B$1.7B
Weighted average shares outstanding$356.9M$355.2M$351.2M$355.7M$356.1M
Weighted average diluted shares outstanding$362.7M$362M$357.4M$362M$365.8M
Balance sheet
20252024202320222021
Cash and short-term investments$5.93B$4.01B$5.22B$4.12B$4.23B
Net receivables$1.63B$1.36B$1.27B$1.07B$893M
Inventory$1.84B$1.49B$1.22B$893.2M$587.1M
Total current assets$9.78B$7.11B$7.89B$6.25B$5.84B
Property, plant and equipment, net$5.34B$4.78B$3.54B$2.37B$1.88B
Goodwill and intangible assets$381.4M$370.5M$387.8M$398.3M$414.1M
Long-term investments$3.3B$5.06B$2.12B$2.62B$4.42B
Total non-current assets$10.9B$11.7B$7.55B$6.72B$7.71B
Total assets$20.6B$18.8B$15.4B$13B$13.6B
Accounts payable$255.1M$193.4M$188.7M$147M$121.2M
Short-term debt$39M$33.5M$0.00$0.00$0.00
Deferred revenue$506.7M$468.8M$446.1M$397.3M$377.2M
Total current liabilities$2.01B$1.75B$1.66B$1.42B$1.15B
Long-term debt$263.8M$112.5M$0.00$0.00$87M
Deferred revenue, non-current$91.4M$54.1M$45.6M$41M$36.8M
Total non-current liabilities$683.3M$563.7M$385.5M$439.3M$453.7M
Capital lease obligations$131.9M$112.5M$0.00$0.00$87M
Total liabilities$2.69B$2.31B$2.04B$1.86B$1.6B
Common stock$400K$400K$400K$400K$400K
Retained earnings$7.01B$6.8B$4.74B$3.5B$4.76B
Accumulated other comprehensive income (loss)$43.3M-$-51.3M-$-12.2M-$-162.5M-$-24.2M
Total equity$17.9B$16.5B$13.4B$11.1B$12B
Total investments$5.87B$7.05B$4.59B$5.16B$7.36B
Total debt$302.8M$146M$0.00$0.00$87M
Net debt-$-3.07B-$-1.88B-$-2.75B-$-1.58B-$-1.2B
Cash flow statement
20252024202320222021
Net income$2.88B$2.34B$1.82B$1.34B$1.73B
Depreciation and amortization$677.1M$462M$435.2M$365.8M$310.2M
Stock-based compensation$788.2M$676.8M$598.2M$513.2M$449.2M
Change in working capital-$-1.27B-$-919.3M-$-777.6M-$-619.1M-$-368.1M
Accounts receivable-$-301.7M-$-95.9M-$-186.3M-$-159.3M-$-142.3M
Inventory-$-1.06B-$-830M-$-712.5M-$-546.6M-$-256M
Accounts payable$57.9M-$-400K$41.7M$21.3M$36M
Net cash provided by operating activities$3.03B$2.42B$1.81B$1.49B$2.09B
Investments in property, plant and equipment-$-539.8M-$-1.11B-$-1.06B-$-532.4M-$-353.5M
Acquisitions, net-$-13.9M-$-1M-$-8.9M-$-12.8M-$-8.7M
Net cash used for investing activities$665.8M-$-3.27B-$-360.1M$1.37B-$-2.46B
Common stock issued$350.3M$429.4M$296.3M$0.00$276.5M
Common stock repurchased-$-2.3B$0.00-$-416.3M-$-2.61B$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities-$-2.36B$150.9M-$-287.6M-$-2.57B$43M
Net change in cash$1.35B-$-707.7M$1.17B$294.7M-$-332.5M
Cash at end of period$3.41B$2.06B$2.77B$1.6B$1.31B
Operating cash flow$3.03B$2.42B$1.81B$1.49B$2.09B
Capital expenditure-$-539.8M-$-1.11B-$-1.06B-$-532.4M-$-353.5M
Free cash flow$2.49B$1.3B$749.6M$958.4M$1.74B
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Intuitive Surgical, Inc.

        Intuitive Surgical, Inc. is a leading medical technology firm dedicated to advancing patient care by developing, producing, and commercializing sophisticated tools. These innovations empower medical professionals to deliver superior, accessible, and less-invasive treatment options to patients both within the United States and across international markets. Its flagship offering, the da Vinci Surgical System, facilitates intricate operations through a minimally disruptive approach. Expanding beyond surgical applications, the company also provides the Ion endoluminal system, designed for diagnostic interventions like minimally invasive lung biopsies. Complementing its primary systems, Intuitive Surgical supplies a comprehensive array of instruments, including stapling tools, energy devices, and essential core components. Furthermore, it offers structured training programs to ensure proficient use of its technology, alongside extensive customer support services encompassing installation, repairs, and ongoing maintenance. The firm also integrates digital capabilities to deliver unified, connected solutions that optimize hospital performance through actionable insights. Established in 1995, Intuitive Surgical maintains its corporate headquarters in Sunnyvale, California.

        CEO
        David J. Rosa
        Employees
        17.02K
        Beta
        1.46

        Included in

        Explore

        Frequently asked questions

        What is the intrinsic value of Intuitive Surgical, Inc. (ISRG)?

        Intuitive Surgical, Inc. (ISRG) is currently overvalued based on the InvestorsCraft IC model — IC value is 20–50% below the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is ISRG undervalued?

        ISRG trades at a price of $399.05 (Nov 21, 2026): overvalued — IC value is 20–50% below the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.